Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Alector $240 million stock offering
Davis Polk advised the underwriters in connection with Alector, Inc.’s $240 million public offering of 9,602,500 shares of…
Black Diamond Therapeutics $231.3 million IPO
Davis Polk advised the joint book-running managers in connection with an initial public offering of 10,586,316 shares…
Denali Therapeutics $207 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $207…
Zai Lab $300 million follow-on offering of ADSs
Davis Polk advised Zai Lab Limited in connection with its follow-on offering of approximately $300 million of American…
Applied Therapeutics $143.4 million stock offering
Davis Polk advised the underwriters in connection with the SEC-registered offering of 3,152,712 shares of common stock of…
I-Mab $103.7 million IPO and Nasdaq listing
Davis Polk advised the underwriters on the SEC-registered initial public offering by I-Mab of 7,407,400 American depositary…
Davis Polk Advises Charles River on Its Acquisition of HemaCare
Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of…
Davis Polk Advises Notre Dame Intermédica on Its R$5.0 Billion Equity Offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Notre Dame…
Forty Seven, Inc. $195.6 Million Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $195…
Constellation Pharmaceuticals Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the …